抗肝纤维化治疗研究的若干问题

蔡卫民

抗肝纤维化治疗研究的若干问题

蔡卫民

浙江大学医学院附属第一医院传染病研究所传染病诊治国家重点实验室

详细信息

中图分类号: R575.2
计量
- 文章访问数: 3286
- HTML全文浏览量: 20
- PDF下载量: 1411
- 被引次数: 0
出版历程
- 出版日期: 2011-03-20

Some problems in anti-fibrotic therapies

Cai WeiMin

摘要

摘要: 目前全球都较重视抗肝纤维化的研究,介绍抗肝纤维化治疗的靶点,讨论如何在临床前通过体外和体内模型筛选出有效的抗肝纤维化药物。回顾抗肝纤维化药研究进展,总结临床研究的要求与存在的困难。
- 肝硬化 /
- 肝炎,慢性
Abstract: More and more research focuses on the anti-fibrotic therapy worldwide.The purposes of this review are to introduce the therapy targets of anti-fibrosis,discuss how to perform preclinical screening and effective development of anti-fibrotic drugs based on the in vitro and in vivo models,the progress of anti-fibrosis by chemical compounds and the summary of the demand and problems exist in clinical validation.
- liver cirrhosis /
- hepatitis

HTML全文

参考文献(46)

[1]Schuppan D,Friedman S.Antifibrotic therapy:Translation into the clinic[J].Hepatology,2009,50(Suppl 4):100A.

[2]Schuppan D,Popov Y.Targeting liver fibrosis:Strategies for development and validation of antifibrotic therapies[J].Hepatology,2009,50(4):1294-1306.

[3]Wells RG.Liver fibrosis:challenges of the new era[J].Gastroenterology,2009,136(2):387-388.

[4]蔡卫民.认识肝纤维化[J].健康研究,2010,30(3):161-166.

[5]Taura K,Miura K,Iwaisako K,et al.Hepatocytes fo not undergo epithelial-mesenchymal transition in liver fibrosis in mice[J].Hepatology,2010,51(3):1027-1036.

[6]Wells RG.The epithelial-to-mesenchymal transition in liver fibrosis:Here today,gone tomorrow?[J].Hepatology,2010,51(3):737-740.

[7]Dranoff JA,Wells RG.Portal fibroblasts:Underappreciated mediators of biliary fibrosis[J].Hepatology,2010,51(4):1438-1444.

[8]Zhang DW,Bian H.No contribution to liver fibrosis,but possible carcinogenesis?[J].Hepatology,2010,51(4):1468-1469.

[9]高建蓉,刘焱文,李昌煜,等.鳖甲抗肝纤维化活性物质的筛选与分离鉴定[J].中华肝脏病杂志,2010,18(5):346-352.

[10]Weng H,Mertens PR,Gressner AM,et al.IFNγabrograters profibrogenic TGFβsignaling in liver by targeting expression of inhibitory and receptor Smads[J].J Hepatol,2007,46(2):295-303.

[11]Saile B,Eisenbach C,El-Armouche H,et al.Antiapoptotic effect of interferon-alpha on hepatic stellate cells(HSC):a novel pathway of IFN-alpha signal transduction via Janus kinase 2(JAK2)and caspase-8[J].Eur J Cell Biol,2003,82(1):31-41.

[12]Fickert P,Stoger U,Fuchsbicher A,et al.A new xenobiotac-induced of sclerosing cholangitis and biliary fibrosis[J].Am J pathol,2007,171(2):527-536.

[13]翁红雷,蔡卫民,汪国运,等.γ-干扰素抗大鼠肝纤维化的初步研究[J].中西医结合肝病杂志,1998,8(2):91-93.

[14]翁红雷,蔡卫民,汪国运,等.不同剂量γ-干扰素治疗大鼠实验性肝纤维化疗效研究[J].中华传染病,2001,19(5):26-29.

[15]王宝恩,王志实,殷葭荑,等.实验性免疫性肝纤维化模型的研究[J].中华医学杂志,1989,69(2):503-505.

[16]陈峰,蔡卫民,陈智,等.日本血吸虫病兔胶原合成与降解转录水平的研究[J].中国寄生虫学与寄生虫病,2001,19(5):76-79.

[17]汪国运,蔡卫民,王金泉,等.肝纤维组织学量化诊断的实验研究[J].中华肝脏病杂志,1998,6(4):201-202.

[18]陶君,夏琦,蔡卫民,等.安珐特与γ-干扰素抗肝纤维化比较研究[J].中西医结合肝病杂志,2006,16(6):358-376.

[19]Sobrevals L,Rodriguez C,Romero-Trevejo JL,et al.Insulin-like growth factor 1 gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats[J].Hepatology,2010,5(3):912-921.

[20]Moreno M,Chaves JF,Sancho-Bru P,et al.Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans[J].Hepatology,2010,51(3):974-985.

[21]Douglass A,Wallace K,Parr R,et al.Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury[J].J Hepatol,2008,49(1):88-98.

[22]Sato Y,Murase K,Kato J,et al.Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone[J].Nat Biotechnol,2008,26(4):431-442.

[23]Schoemaker MH,Rots MG,Beljaars L,et al.PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells[J].Mol Pharm,2008,5(3):399-406.

[24]Rockey DC.Current and future anti-fibrotic therapies for chronic liver disease[J].Clin Liver Dis,2008,12(4):939-962.

[25]Mannaerts I,Nuytten NR,Rogiers V,et al.Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cell in Vitro and in Viro[J].Hepatology,2010,51(2):603-614.

[26]Ikura Y,Iwasa Y,Ueda M.Valproic acid administration for hepatic fibrosis:a balance between antifibrotic efficacy and hepatotoxicity[J].Hepatology,2010,51(6):2227-2228.

[27]Moreno M,Gonzalo T,Kok RJ,et al.Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats[J].Hepatology,2010,51(3):942-952.

[28]McHutchison J,Goodman Z,Patel K,et al.Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection[J].Gastroenterology,2010,138(4):1365-1373.

[29]Harrison SA.Thiazolidinedione therapy for nonalcoholic steatohepatitis:go,stop,or proceed with caution?[J].Hepatology,2010,51(2):366-369.J Clini Hepatol,March 2011,Vol.27,No.3

[30] 任光辉.临床血吸虫病学[M].北京:人民卫生出版社,2009:273-302.

[31]Fontana RJ.Side effects of long-term oral antiviral therapy for hepatitis B[J].Hepatology,49(5):s185-195.

[32]European Association For The Study of the Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B[J].J Hepatol,2009,50(2):227-242.

[33]Lok AS,McMahon BJ.Chronic hepatitis B:update[J].Hepatology,2009,50:661-662.

[34] 任红.慢性乙型肝炎治疗的热点和难点[J].中华肝脏病杂志,2009,17(10):721.

[35]Weng HL,Wang BE,Jia JD,et al.Effect of IFNγon hepatic fibrosis in chronic hepatitis B virus infection:A randomized controlled study[J].Chin Gastroenterol Hepatol,2005,3(8):819-828.

[36]Prockros P,Jeffers L,Afdhal N,et al.Final results of A do-uble-blind,placebo-controlled trial of the antifibrotic efficacy of interferon-rlb in chronic hepatitis C patients with advanced fibrosis or cirrhosis[J].Hepatology,2007,45(1):569-578.

[37]Weng HL,Ciuclan L,Liu Y,et al.Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes[J].Hepatology,2007,46(4):1257-1270.

[38]陈煜,王宝恩,贾德东,等.慢性乙型肝炎肝纤维化程度无创伤评估[J].中华肝脏病杂志,2003,11(5):354-357.

[39]Garcia-Tsao G,Friedmen S,Iredale J,et al.Now there are many(stages)where before there was one:In search of a pathophysiological classification of cirrhosis[J].Hepatology,2010,51(4):1095-1106.

[40] 中华肝病学会.肝纤维化诊断及疗效评估共识[J].中华肝脏病杂志,2006,10(5):327-328.

[41]中西医结合学会肝病分会.肝纤维化中西结合诊疗指南[J].中华肝脏病杂志,2006,14(11):866-870.

[42]翁红雷,蔡卫民,王宝恩,等.重组干扰素γ治疗慢性乙型肝炎肝纤维化临床研究[J].中华医学杂志,2003,83(11):943-947.

[43]Muir AJ,Sylvestre PB,Rockey DC.Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection[J].J Viral Hepat,2006,13(2):322-328.

[44]Rockey DC,Caldwell SH,Goodman,et al.Liver biopsy[J].Hepatology,2009,49(3):1017-1044.

[45]Castéra L,Foucher J,Bernard PH,et al.Pitfalls of liver sfiffness measurement:A 5-year prospective study of 13,369 examinations[J].Hepatology,2010,51(3):828-835.

[46]Weng HL,Liu Y,Chen JL,et al.The etiology of liver da-mage imparts cytokines transforming growth factor betal or interleukine-13 as driving forces in fibrogenesis[J].Hepatology,2009,50(1):230-243.

施引文献

资源附件(0)

访问统计